Invesco Pharmaceuticals ETFPJP
PJP
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.93% more ownership
Funds ownership: 23.12% [Q3] → 24.05% (+0.93%) [Q4]
2% less capital invested
Capital invested by funds: $66.3M [Q3] → $64.7M (-$1.62M) [Q4]
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
5% less funds holding
Funds holding: 97 [Q3] → 92 (-5) [Q4]
36% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 25
Research analyst outlook
We haven’t received any recent analyst ratings for PJP.
Financial journalist opinion
Neutral
Seeking Alpha
6 days ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
Zacks Investment Research
2 weeks ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
If you're interested in broad exposure to the Healthcare - Pharma segment of the equity market, look no further than the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005.
Neutral
Zacks Investment Research
2 months ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Launched on 06/23/2005, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
Negative
Seeking Alpha
2 months ago
PJP: Big Pharma Concentration Risks Amid Looming Confirmation Of RFK Jr.
The article discusses six major constituents of the Invesco Pharmaceuticals ETF PJP: Pfizer, Amgen, Gilead Sciences, AbbVie, Bristol-Myers Squibb, and Merck & Co. The focus lies on the identification of geographic and product-related concentration risks, especially in light of Trump 2.0 and the potential confirmation of RFK Jr. as Secretary of the HHS. In addition, dependence on vaccine sales will be discussed, and a review of various credit metrics well be conducted.
Neutral
Zacks Investment Research
2 months ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the Invesco Pharmaceuticals ETF (PJP), a passively managed exchange traded fund launched on 06/23/2005.
Neutral
Zacks Investment Research
4 months ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Neutral
Zacks Investment Research
4 months ago
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
Neutral
Zacks Investment Research
6 months ago
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
The Invesco Pharmaceuticals ETF (PJP) made its debut on 06/23/2005, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Positive
Seeking Alpha
6 months ago
PJP: A Dynamic Pharma Fund
Bullish on pharmaceuticals and health care due to relative momentum and preference for "need" sectors over cyclical ones. The Invesco Pharmaceuticals ETF provides exposure to select pharmaceutical stocks with specific criteria for selection and a dynamic approach. The fund holds 24 stocks, primarily in pharmaceuticals, biotech, and healthcare equipment, with heavyweights like AbbVie, Regeneron, Eli Lilly, and Abbott Laboratories.
Positive
Zacks Investment Research
6 months ago
Pharma ETFs in Focus Post Solid Q2 Earnings
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.
Charts implemented using Lightweight Charts™